CARsgen Therapeutics Holdings Limited announced that CARsgen has initiated patient enrollment for Phase 2 of the clinical trial for CT041 in the U.S. for the treatment of CLDN18.2 positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ) in patients who have failed at least 2 prior lines of systemic therapies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.54 HKD | -2.81% | -10.06% | -14.77% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.77% | 419M | |
+15.85% | 122B | |
+18.91% | 113B | |
+7.51% | 22.84B | |
-18.63% | 20.72B | |
-13.76% | 16.39B | |
-15.66% | 16.51B | |
-43.53% | 15.83B | |
+1.75% | 13.49B | |
+28.07% | 11.67B |
- Stock Market
- Equities
- 2171 Stock
- News CARsgen Therapeutics Holdings Limited
- CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041